Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

OBJECTIVE: To evaluate the impact of adalimumab on health-related quality of life (HRQOL) for patients with moderate to severe plaque psoriasis. BACKGROUND: Psoriasis is a chronic, inflammatory, immune-mediated disease that has a significant impact on patients' HRQOL. Adalimumab is a fully huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Revicki, Dennis A, Menter, Alan, Feldman, Steven, Kimel, Miriam, Harnam, Neesha, Willian, Mary K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579425/
https://www.ncbi.nlm.nih.gov/pubmed/18831744
http://dx.doi.org/10.1186/1477-7525-6-75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579425/
https://www.ncbi.nlm.nih.gov/pubmed/18831744
http://dx.doi.org/10.1186/1477-7525-6-75

Ejemplares similares